ASX ANNOUNCEMENT

19 November 2024

Results of Annual General Meeting

Biome Australia Limited (ASX:BIO, "Biome" or "the Company"), announces in accordance with Listing Rule 3.13.2 and Section 251AA of the Corporations Act, the details of the resolutions and the proxies received in respect of each resolution are as set out in the attached report.

-Ends-

Authorised by the Board.

About Biome Australia Limited

Biome Australia develops, licenses, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. Biome aims to improve health outcomes and quality of life and make its products accessible to all.

Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with some of the world's leading organisations in microbiome research and development, Biome produced several unique live biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and efficacy to create its flagship range of complementary medicines: Activated Probiotics®.

Supported by clinical research, including randomised double-blind placebo-controlled trials, Activated Probiotics help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-only distribution, Biome is committed to educating health professionals on the newfound systemic health effects of the gut microbiota, helping them to provide innovative, evidence-based natural medicines for the management of some of humanity's most prevalent and chronic health concerns.

For more information visit: www.biomeaustralia.com

Investor Relations
Jo Power
+61 (3) 9017 5800
corporate@biomeaustralia.com

BIOME | AUSTRALIA GROUP The Microbiome Health Company

ACTIVATED PROBIOTICS® ACTIVATED NUTRIENTS®

Biome Australia Limited Annual General Meeting Tuesday, 19 November 2024
Voting Results

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2

Resolution details		Instructions given to validly appoint proxies (as at proxy close)				Number of votes cast on the poll (if decided by poll)			Voting Method	Resolution Result
Resolution	**Resolution Type**	**For**	**Against**	**Proxy's Discretion**	**Abstain**	**For**	**Against**	**Abstain**		**Carried/ Not Carried**
Resolution 1 Adoption of Remuneration Report	Non-Binding	21,129,140 **90.17%**	2,114,195 **9.02%**	190,044 **0.81%**	27,231,469	43,965,108 **95.41%**	2,114,195 **4.59%**	28,643,333	Poll	Carried
Resolution 2 Re-election of Director – Ms Dominique Fisher	Ordinary	48,336,089 **95.50%**	2,085,667 **4.12%**	190,044 **0.38%**	53,048	72,583,921 **97.21%**	2,085,667 **2.79%**	53,048	Poll	Carried
Resolution 3 Ratification of prior issue of 2,500,000 unlisted options	Ordinary	49,871,356 **99.33%**	144,400 **0.29%**	192,044 **0.38%**	457,048	73,921,188 **99.54%**	344,400 **0.46%**	457,048	Poll	Carried
Resolution 4 Renewal of Shareholder Approval of Employee Incentive Plan	Ordinary	20,913,112 **89.08%**	2,374,223 **10.11%**	190,044 **0.81%**	27,187,469	43,749,080 **94.85%**	2,374,223 **5.15%**	28,599,333	Poll	Carried
Resolution 5 Approval of 7.1A Mandate	Special	48,208,989 **95.22%**	2,230,067 **4.40%**	190,044 **0.38%**	35,748	60,256,821 **96.43%**	2,230,067 **3.57%**	12,235,748	Poll	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.